We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Post Coronary Artery Bypass Graft (CABG) Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000463
Recruitment Status : Completed
First Posted : October 28, 1999
Last Update Posted : April 14, 2016
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)

Brief Summary:
To determine the relative effectiveness of moderate versus more aggressive lipid lowering, and of low dose anticoagulation versus placebo, in delaying saphenous vein coronary bypass graft atherosclerosis and preventing occlusion of saphenous grafts of patients with saphenous vein coronary bypass grafts placed 1 to 11 years previously.

Condition or disease Intervention/treatment Phase
Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia Drug: lovastatin Drug: cholestyramine Drug: warfarin Phase 3

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Masking: Double
Primary Purpose: Prevention
Study Start Date : April 1987
Study Completion Date : December 1998

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Men and women between 1 and 11 years post-CABG. Patients had two completely independent saphenous vein grafts that were patent. Patients had an LDL-cholesterol between 130 and 175 with plasma triglycerides below 300 mg/dl.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000463

Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Layout table for investigator information
OverallOfficial: Genell Knatterud Maryland Medical Research Institute
Study Data/Documents: Individual Participant Data Set  This link exits the ClinicalTrials.gov site
Identifier: CABG
NHLBI provides controlled access to IPD through BioLINCC. Access requires registration, evidence of local IRB approval or certification of exemption from IRB review, and completion of a data use agreement.

Fox NL, LoPresti F, Hoogwerf B, Knatterud G, Linquist R, Czajkowski S. Self-administered quality of life forms: experience from the Post Coronary Artery Bypass Graft Studies. Controlled Clin Trials 1993;14:402.
Campeau L, Knatterud GL, White C, Domanski M, Geller N, Robernsberg Y and the Post CABG Studies Principal Investigators. The NHLBI Post Coronary Artery Bypass Graft Clinical Trial (Post CABG): Angiographic outcomes. Proceedings of the colloquium "Progression and Regression of Coronary Atherosclerosis: Observations from Lipid Intervention Studies," In Press

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00000463    
Other Study ID Numbers: 52
First Posted: October 28, 1999    Key Record Dates
Last Update Posted: April 14, 2016
Last Verified: August 2004
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases
Heart Diseases
Coronary Disease
Myocardial Ischemia
Pathologic Processes
Vascular Diseases
L 647318
Cholestyramine Resin
Anticholesteremic Agents
Hypolipidemic Agents
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors